Neutralizing antibodies for the treatment of COVID-19

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

(2020) Ning Wang et al.   Frontiers in Microbiology

Signals of Th2 immune response from COVID-19 patients requiring intensive care

(2020) Luca Roncati et al.   ANNALS OF HEMATOLOGY

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

(2020) J.-M. Michot et al.   ANNALS OF ONCOLOGY

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Identification of Human Single-Domain Antibodies against SARS-CoV-2

(2020) Yanling Wu et al.   Cell Host & Microbe

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

(2020) Xiaohua Chen et al.   CLINICAL INFECTIOUS DISEASES

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

(2020) Chenguang Shen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Structural basis of receptor recognition by SARS-CoV-2

(2020) Jian Shang et al.   NATURE

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

(2020) Jingyou Yu et al.   SCIENCE

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

(2020) Yunlong Cao et al.   CELL

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

(2020) Michael J. Joyner et al.   MAYO CLINIC PROCEEDINGS

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

(2020) Jiangdong Huo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

(2020) Alina Baum et al.   SCIENCE

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

(2020) Thomas F. Rogers et al.   SCIENCE

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

(2020) Christina M. Eckhardt et al.   Trials

A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

(2020) Jonathan Rilinger et al.   Trials

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

(2020) Wei Li et al.   CELL

Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

(2020) Sean T. H. Liu et al.   NATURE MEDICINE

Learning from the past: development of safe and effective COVID-19 vaccines

(2020) Shan Su et al.   NATURE REVIEWS MICROBIOLOGY

The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

(2020) Aoife Cotter et al.   Trials

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

(2020) Liqiang Feng et al.   Nature Communications

An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction

(2020) Leo Hanke et al.   Nature Communications

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain

(2020) Xiaojing Chi et al.   Nature Communications

Convalescent plasma is ineffective for covid-19

(2020) Elizabeth B Pathak   BMJ-British Medical Journal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

(2020) Anup Agarwal et al.   BMJ-British Medical Journal

Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

(2020) Eric Salazar et al.   AMERICAN JOURNAL OF PATHOLOGY

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

(2019) Yushun Wan et al.   JOURNAL OF VIROLOGY

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

(2011) M. Bolles et al.   JOURNAL OF VIROLOGY

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

(2009) Lanying Du et al.   NATURE REVIEWS MICROBIOLOGY